Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges

Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges
Published on :

The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.

Why Philadelphia is Poised to Become a Top Cell and Gene Therapy Cluster

The Discovery Labs King of Prussia PA
Published on :

The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.

5 Questions with Doug White, Senior Vice President, Devices Business Unit Head, Emergent BioSolutions

Published on :

Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women’s Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc.

In Conversation with Tia Lyles-Williams, Founder and CEO of LucasPye BIO and HelaPlex

Published on :

Tia Lyles-Williams, the founder & CEO of LucasPye BIO (LPB) and HelaPlex, is on a mission to lower development and manufacturing costs for emerging life science companies while bringing greater diversity to the life science industry.

5 Questions with Mike O’Mara, VP of Industrial Business Services, Miltenyi Biotec

Published on :

Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.

5 Questions with Nick Droste, Supervisor, Emergent BioSolutions Postfill Manufacturing Supervisor

Published on :

Andrew Davis is Vice President at Scheer Partners and helps run the scientific real estate practice. Andrew lives in Maryland but assists scientific companies identify, negotiate, and build space in the Biohealth Capital Region, Philadelphia / Greater PA, and Massachusetts.